| DrugRepV_0784 | Deferasirox | Various | Tansfusional hemosiderosis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (87.47 %) | Approved | 27476412 |
| DrugRepV_0809 | Deferoxamine Mesylate | Various | Iron or aluminum toxicity | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (67.29 %) | Approved | 27476412 |
| DrugRepV_0861 | Pralidoxime Chloride | Various | Poisoning | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.51 %) | Approved, Vet approved | 27476412 |
| DrugRepV_1050 | Aminohippurate Sodium | Various | Measure effective renal plasma flow | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.04 %) | Approved | 27476412 |
| DrugRepV_1105 | Flumazenil | Various | Anesthesia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.315 %) | Approved | 27476412 |
| DrugRepV_1152 | Metyrapone | Various | Cushing syndrome | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.775 %) | Approved, Investigational | 27476412 |
| DrugRepV_1256 | Diatrizoate Meglumine | Various | X-ray contrast medium, gastrointestinal studies, angiography, and urography | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.205 %) | Approved | 27476412 |
| DrugRepV_1356 | Fomepizole | Various | Ethylene glycol poisoning | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.72 %) | Approved, Vet approved | 27476412 |
| DrugRepV_1381 | Amifostine | Various | Nephrotoxicity and Xerostomia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.31 %) | Approved | 27476412 |
| DrugRepV_1413 | Dexrazoxane | Various | Cardiomyopathy | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.42 %) | Approved | 27476412 |
| DrugRepV_1423 | Leucovorin Calcium Pentahydrate | Various | Osteosarcoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (42.875 %) | Approved | 27476412 |
| DrugRepV_2255 | Deferasirox | Various | Tansfusional hemosiderosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.76811009 %) | Approved | 27742486 |
| DrugRepV_2260 | Calcium Levofolinate | Various | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.51423322 %) | NA | 27742486 |
| DrugRepV_2272 | Flumazenil | Various | Anesthesia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.99459989 %) | Approved | 27742486 |
| DrugRepV_2311 | Inulin | Various | Diabetes mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.04438602 %) | Approved, Investigational, Nutraceutical | 27742486 |
| DrugRepV_2341 | Gadodiamide | Various | Intravenous use in MRI to visualize lesions | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.33933034 %) | Approved, Investigational | 27742486 |
| DrugRepV_2492 | Dexrazoxane Hydrochloride | Various | Cardiomyopathy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.23802475 %) | Approved | 27742486 |
| DrugRepV_2628 | Leucovorin calcium | Various | Osteosarcoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8474034 %) | Approved | 27742486 |